CIAS
MDGL icon

Capital Investment Advisory Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Capital Investment Advisory Services’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$9K – 1430
2019
Q2 		$9K Buy
+100
New +$10.7K ﹤0.01% 996

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Investment Advisory Services's MDGL Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2019, closing a stake of 100 shares — an estimated $9K sold.

Capital Investment Advisory Services first reported a position in MDGL in Q2 2019 and held it in 1 quarter. The position peaked at $9K in Q2 2019. 111 funds tracked by Wall St. Rank hold MDGL as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Madrigal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 100 Madrigal Pharmaceuticals shares in Q3 2019, an estimated $9K.
  • Capital Investment Advisory Services first reported a position in Madrigal Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Madrigal Pharmaceuticals position peaked at $9K in Q2 2019.
  • 111 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.